Radius Health to Announce Second Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, August 5, 2021

Rhea-AI Summary

Radius Health, Inc. (Nasdaq: RDUS) will release its second quarter financial results on August 5, 2021, and host a conference call at 8:30 a.m. ET to discuss the results and provide updates. Investors can join the conference at 1 (800) 446-1671 or 1 (847) 413-3362 using conference ID 50202646. A replay will be available later that day. Radius is focused on addressing unmet medical needs in endocrinology and has a pipeline including TYMLOS^® and investigational drugs for osteoporosis and breast cancer.

Positive

• Upcoming second quarter financial results could provide insights into company performance.
• Conference call scheduled for August 5 may enhance investor engagement and transparency.

Negative

• None.

BOSTON, July 20, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Thursday, August 5, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update.

Conference Call Information:
Domestic Dial-In Number: 1 (800) 446-1671
International Dial-In Number: 1 (847) 413-3362
Conference ID: 50202646
Webcast Link: https://edge.media-server.com/mmc/p/3bncvtkf

A replay of the conference call will be available on August 5 at 11:30 a.m. ET and a live audio webcast of the call will be archived on the Company's website for ninety days. To access the replay, dial (855) 859-2056 or (404) 537-3406 for International, using conference ID number 3659752. The live audio webcast of the call can be accessed from the Investors section of the Company’s website, https://ir.radiuspharm.com/events-and-presentations. The full text of the announcement and financial results will also be available on the Company’s website.

About Radius

Radius is a commercial biopharmaceutical company committed to serving patients with unmet medical needs in endocrinology and other therapeutic areas. Radius’ lead product, TYMLOS^® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.

Investor & Media Relations Contact:
Ethan Holdaway
Email: investor-relations@radiuspharm.com
Phone: (617) 583-2017

 

FAQ

When will Radius Health release its second quarter results?

Radius Health will release its second quarter financial results on August 5, 2021.

What time is the conference call for Radius Health's Q2 results?

The conference call is scheduled for 8:30 a.m. ET on August 5, 2021.

How can I listen to the Radius Health conference call?

You can listen by dialing 1 (800) 446-1671 or 1 (847) 413-3362 with conference ID 50202646.

What is Radius Health's stock ticker symbol?

Radius Health's stock ticker symbol is RDUS.

Where can I find the replay of the Radius Health conference call?

The replay will be available on August 5 at 11:30 a.m. ET on Radius Health's website.